^
    11d
    Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer. (PubMed, Front Oncol)
    Selpercatinib and pralsetinib are the most frequently studied RET inhibitors. Notably, research on next-generation RET inhibitors as monotherapy approaches (e.g., LOXO-260, enbezotinib, SY-5007 and TY-1091) is currently underway...While selective RET inhibitors have demonstrated therapeutic potential, concerns regarding drug resistance and toxicity persist. Therefore, future strategies should prioritize the development of next-generation inhibitors and the optimization of combination regimens to improve outcomes for RET-altered thyroid cancer patients.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib) • SY-5007 • TY-1091 • enbezotinib (TPX-0046) • LOXO-260
    2years
    A Study of TY-1091 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=248, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    TY-1091
    almost3years
    A Study of TY-1091 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=248, Not yet recruiting, TYK Medicines, Inc
    New P1/2 trial • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    TY-1091